Company: APXIF
Filing Date: 2025-06-13
Form Type: F-4/A
Source: 0001213900-25-054324
Chunk: 91

Company: APx Acquisition Corp. I
Filing Date: 2025-06-13
Form: F-4/A
Chunk 91
---
 assets recorded. The Business Combination will be accounted for within the scope of IFRS 2 — Share -basedPayments (“IFRS 2”). As a result, any excess of fair value of the Company Shares issued over the fair value of APx’s identifiable net assets acquired, represent compensation for the service in respect of a stock exchange listing for the Company Shares and is expensed upon consummation. For a discussion summarizing the anticipated accounting treatment of the Business Combination, please see “ Anticipated Accounting Treatment of the Business Combination.” APx Board of Directors’ Reasons for the Approval of the Business Combination The APx Board unanimously approved the Business Combination after consulting with APx’s management and advisors and conducting a comprehensive review of due diligence findings. The APx Board evaluated various factors, including the Company’s competitive position in the healthcare space, combining advanced genomics, microbiome analysis, and artificial intelligence capabilities, as well as its hybrid business -to-business(B2B) and business -to-business-to-consumer(B2B2C) distribution strategies. The Company’s intellectual property portfolio and valuation, considered attractive relative to global public and private comparable companies in the genomics, diagnostics, and healthcare technology sectors, further supported the APx Board’s determination. 11 The APx Board reviewed financial metrics, including revenue and EBITDA comparisons, but due to the emerging nature of the industries in which the Company operates, placed greater emphasis on qualitative factors like the total addressable market, scalability, and operational efficiencies. The APx Board also relied on results from due diligence that assessed the Company’s material contracts, corporate governance, regulatory compliance, financial history, and market opportunities, including potential expansion within Latin America. While acknowledging risks such as the lack of a third -partyfairness opinion and challenges in transitioning to a public company, the Board determined, based on its collective experience and judgment, that the potential strategic and financial benefits to APx and its shareholders outweighed these risks, leading to its unanimous approval of the Business Combination Agreement. See the section entitled “ APx Board of Directors’ Reasons for the Approval of the Business Combination” for more information. Risk Factors In evaluating the proposals to be presented at the Special Meeting, a shareholder should carefully read this proxy statement/prospectus and especially consider the factors discussed in the section entitled “ Risk Factors.” Further, the Company has historically incurred significant losses: $1,322,306, $4,516,095 and $1,291,932 for the six months ended December31,